Dermata Therapeutics Inc., a late-stage biotechnology company, recently announced the results of its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial. The trial, focused on moderate-to-severe acne, met all three primary endpoints, demonstrating statistically significant results versus placebo at the study's conclusion. Results indicated that XYNGARI™ achieved significant separation from placebo after just four weeks of treatment, as well as at the 12-week primary endpoint required by the FDA. Following these positive results, Dermata has initiated additional manufacturing and is evaluating the next steps for the upcoming XYNGARI™ Phase 3 STAR-2 clinical trial, which will be followed by a 9-month extension study.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。